| 前收盘价格 | 54.99 |
| 收盘价格 | 55.28 |
| 成交量 | 83,903 |
| 平均成交量 (3个月) | 670,833 |
| 市值 | 1,599,746,176 |
| 价格/销量 (P/S) | 6.49 |
| 股市价格/股市净资产 (P/B) | 124.01 |
| 52周波幅 | |
| 利润日期 | 10 Aug 2026 |
| 营业毛利率 | -125.70% |
| 营业利益率 (TTM) | -99.16% |
| 稀释每股收益 (EPS TTM) | -4.76 |
| 季度收入增长率 (YOY) | 286.80% |
| 总债务/股东权益 (D/E MRQ) | 1,016.89% |
| 流动比率 (MRQ) | 8.25 |
| 营业现金流 (OCF TTM) | -108.78 M |
| 杠杆自由现金流 (LFCF TTM) | -60.04 M |
| 资产报酬率 (ROA TTM) | -15.14% |
| 股东权益报酬率 (ROE TTM) | -343.83% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | AnaptysBio, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.83 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 5.09% |
| 机构持股比例 | 133.99% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ecor1 Capital, Llc | 31 Mar 2026 | 7,880,094 |
| Sanofi | 30 Jun 2026 | 821,917 |
| Palo Alto Investors Lp | 31 Mar 2026 | 638,161 |
| First Light Asset Management, Llc | 31 Mar 2026 | 565,431 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合